Cumberland Pharmaceuticals Inc (CPIX) 5.90 $CPIX
Cumberland Pharmaceuticals Up 21.2% Since SmarTrend Uptrend Call (CPIX)
Comtex SmarTrend(R) - Thu Feb 12, 10:12AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 6 months, Cumberland Pharmaceuticals has returned 21.24% as of today's recent price of $5.85.
CPIX: 5.90 (+0.04)
Global N-acetylcysteine Industry Report 2015
M2 - Wed Feb 11, 2:24PM CST
Research and Markets (http://www.researchandmarkets.com/research/rdgpq9/global) has announced the addition of the "Global N-acetylcysteine Industry Report 2015" report to their offering. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The N-acetylcysteine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. N-acetylcysteine industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The N-acetylcysteine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - N-acetylcysteine Industry Overview - Global N-acetylcysteine Market Status Analysis - Major Regions N-acetylcysteine Market Status Analysis - Major Countries N-acetylcysteine Market Status and Analysis - Major Companies N-acetylcysteine Market Status and Analysis - N-acetylcysteine Industry Chain and Marketing Channels Analysis - N-acetylcysteine Industry Segment Market Analysis - N-acetylcysteine Industry Development Trend - N-acetylcysteine New Project Investment Feasibility Analysis - Global N-acetylcysteine Industry Research Conclusions Companies Mentioned - BASF - BIONICHE LIFE SCIENCES - CUMBERLAND PHARMACEUTICALS - Donboo Amino Acid - Hubei Jusheng Technology - Hubei Shengbaolai Biological Technology - Manus Aktteva Biopharma LLP - Ningbo Create-BIO ENGINEERING - Ningbo Zhenhai Haide Amino Acid - SWACKER AG - WUXI ENOVO CHEMICAL - Wuhan Grand Hoyo - Wuhan Hezhong Bio-Chemical - Wuhan lullaby pharmaceutical chemical - XYS - Xinyi Hanling Biological Engineering - ZAMBON - ZHANGJIAGANG SPECOM BIOCHEMICAL - Zhangjiagang Huachang Pharmaceutical - Zhangjiagang Shuguang Biological For more information visit http://www.researchandmarkets.com/research/rdgpq9/global
TST.TO: 0.29 (-0.02), CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals Announces Pipeline Expansion With Boxaban(TM) (ifetroban) Oral Capsule
PR Newswire - Wed Feb 11, 7:05AM CST
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban(TM) (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Cumberland has completed manufacturing and received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) submission and Phase II study associated with the product.
CPIX: 5.90 (+0.04)
21.2% Return Seen to Date on SmarTrend Cumberland Pharmaceuticals Call (CPIX)
Comtex SmarTrend(R) - Thu Feb 05, 9:19AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 6 months, Cumberland Pharmaceuticals has returned 21.24% as of today's recent price of $5.85.
CPIX: 5.90 (+0.04)
Phase IV Studies Published Supporting The Safety Of A Shortened Infusion Time Of Caldolor® (ibuprofen) Injection
PR Newswire - Mon Feb 02, 7:30AM CST
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of two Phase IV studies adding to the growing body of literature that support the tolerability and efficacy of a shortened infusion time of Caldolor® (ibuprofen) Injection. The studies included a total of 450 patients enrolled at over 30 leading U.S. medical centers. The new publications reporting on the study results are currently available as open access articles in the journal Clinical Therapeutics.
CPIX: 5.90 (+0.04)
Uptrend Call Working As Cumberland Pharmaceuticals Stock Rises 19.4% (CPIX)
Comtex SmarTrend(R) - Wed Jan 28, 4:48PM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 6 months, Cumberland Pharmaceuticals has returned 19.38% as of today's recent price of $5.76.
CPIX: 5.90 (+0.04)
Uptrend Call Working As Cumberland Pharmaceuticals Stock Rises 26.8% (CPIX)
Comtex SmarTrend(R) - Wed Jan 21, 11:04AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 6 months, Cumberland Pharmaceuticals has returned 26.84% as of today's recent price of $6.12.
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals Shares Up 26.0% Since SmarTrend's Buy Recommendation (CPIX)
Comtex SmarTrend(R) - Wed Jan 07, 9:11AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 5 months, Cumberland Pharmaceuticals has returned 26.01% as of today's recent price of $6.08.
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals Remains Attractive After Rally
Daniel Ward - at Seeking Alpha - Tue Jan 06, 5:00AM CST
CPIX: 5.90 (+0.04)
Pleural Effusion Therapeutics Clinical Trials Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 5:31AM CST
The report "Pleural Effusion Global Clinical Trials Review, H2, 2014" provides data on the Pleural Effusion clinical trial scenario. Pleural effusion (water on the lungs) is the build-up of excess fluid between the layers of the pleura outside the lungs. The pleura are a thin covering that lines the surface of the lungs and the inside of the chest wall outside the lungs. The type of fluid that forms a pleural effusion may be categorized as either transudate or exudate. There are many causes of pleural effusions. Some major causes are Congestive heart failure, Kidney failure, Infection, Malignancy, Pulmonary embolism, Hypoalbuminemia, Cirrhosis & Trauma. Approximately 1.5 million pleural effusions are diagnosed in the United States each year. Complete Report is Available @ http://www.reportsnreports.com/reports/322321...-2014.html .
MRK: 58.81 (-0.07), LLY: 70.56 (+0.03), CPIX: 5.90 (+0.04)
Shares of CPIX Up 19.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 23, 11:55AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 5 months, Cumberland Pharmaceuticals has returned 19.17% as of today's recent price of $5.75.
CPIX: 5.90 (+0.04)
Why Cumberland Pharmaceuticals Is A Buy After Q3 Earnings
Daniel Ward - at Seeking Alpha - Thu Nov 06, 8:29AM CST
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals EPS of $0.04
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 11:47PM CST
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals' (CPIX) CEO J. Kazimi on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:01PM CST
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 04, 3:05PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2014 financial results.
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals To Announce Third Quarter 2014 Financial Results On November 4, 2014
PR Newswire - Tue Oct 21, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2014 financial results after the market closes on Tuesday, November 4, 2014. A conference call and live Internet webcast will be held on Tuesday, November 4, 2014, at 4:30 p.m. Eastern Time to discuss the results.
CPIX: 5.90 (+0.04)
Caldolor® Safely Treats Fever In Hospitalized Children
PR Newswire - Tue Oct 14, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that treatment with intravenous ibuprofen was superior in reducing temperatures in hospitalized, febrile pediatric patients when compared to treatment with oral or suppository acetaminophen. These results were presented at the American Academy of Pediatrics National Conference & Exhibition in San Diego, California.
CPIX: 5.90 (+0.04)
Caldolor® Provides Favorable Inflammatory Response Results In Laparoscopic Cholecystectomy Surgery Patients
PR Newswire - Fri Oct 10, 2:11PM CDT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that preoperative intravenous ibuprofen improved overall quality of recovery in patients undergoing laparoscopic cholecystectomy surgery. These results will be presented at the American Anesthesiology 2014 Annual Meeting in New Orleans, Louisiana.
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals Up 21.2% Since SmarTrend Uptrend Call (CPIX)
Comtex SmarTrend(R) - Thu Feb 12, 10:12AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 6 months, Cumberland Pharmaceuticals has returned 21.24% as of today's recent price of $5.85.
CPIX: 5.90 (+0.04)
Global N-acetylcysteine Industry Report 2015
M2 - Wed Feb 11, 2:24PM CST
Research and Markets (http://www.researchandmarkets.com/research/rdgpq9/global) has announced the addition of the "Global N-acetylcysteine Industry Report 2015" report to their offering. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The N-acetylcysteine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. N-acetylcysteine industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The N-acetylcysteine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - N-acetylcysteine Industry Overview - Global N-acetylcysteine Market Status Analysis - Major Regions N-acetylcysteine Market Status Analysis - Major Countries N-acetylcysteine Market Status and Analysis - Major Companies N-acetylcysteine Market Status and Analysis - N-acetylcysteine Industry Chain and Marketing Channels Analysis - N-acetylcysteine Industry Segment Market Analysis - N-acetylcysteine Industry Development Trend - N-acetylcysteine New Project Investment Feasibility Analysis - Global N-acetylcysteine Industry Research Conclusions Companies Mentioned - BASF - BIONICHE LIFE SCIENCES - CUMBERLAND PHARMACEUTICALS - Donboo Amino Acid - Hubei Jusheng Technology - Hubei Shengbaolai Biological Technology - Manus Aktteva Biopharma LLP - Ningbo Create-BIO ENGINEERING - Ningbo Zhenhai Haide Amino Acid - SWACKER AG - WUXI ENOVO CHEMICAL - Wuhan Grand Hoyo - Wuhan Hezhong Bio-Chemical - Wuhan lullaby pharmaceutical chemical - XYS - Xinyi Hanling Biological Engineering - ZAMBON - ZHANGJIAGANG SPECOM BIOCHEMICAL - Zhangjiagang Huachang Pharmaceutical - Zhangjiagang Shuguang Biological For more information visit http://www.researchandmarkets.com/research/rdgpq9/global
TST.TO: 0.29 (-0.02), CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals Announces Pipeline Expansion With Boxaban(TM) (ifetroban) Oral Capsule
PR Newswire - Wed Feb 11, 7:05AM CST
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban(TM) (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Cumberland has completed manufacturing and received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) submission and Phase II study associated with the product.
CPIX: 5.90 (+0.04)
21.2% Return Seen to Date on SmarTrend Cumberland Pharmaceuticals Call (CPIX)
Comtex SmarTrend(R) - Thu Feb 05, 9:19AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 6 months, Cumberland Pharmaceuticals has returned 21.24% as of today's recent price of $5.85.
CPIX: 5.90 (+0.04)
Phase IV Studies Published Supporting The Safety Of A Shortened Infusion Time Of Caldolor® (ibuprofen) Injection
PR Newswire - Mon Feb 02, 7:30AM CST
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of two Phase IV studies adding to the growing body of literature that support the tolerability and efficacy of a shortened infusion time of Caldolor® (ibuprofen) Injection. The studies included a total of 450 patients enrolled at over 30 leading U.S. medical centers. The new publications reporting on the study results are currently available as open access articles in the journal Clinical Therapeutics.
CPIX: 5.90 (+0.04)
Uptrend Call Working As Cumberland Pharmaceuticals Stock Rises 19.4% (CPIX)
Comtex SmarTrend(R) - Wed Jan 28, 4:48PM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 6 months, Cumberland Pharmaceuticals has returned 19.38% as of today's recent price of $5.76.
CPIX: 5.90 (+0.04)
Uptrend Call Working As Cumberland Pharmaceuticals Stock Rises 26.8% (CPIX)
Comtex SmarTrend(R) - Wed Jan 21, 11:04AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 6 months, Cumberland Pharmaceuticals has returned 26.84% as of today's recent price of $6.12.
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals Shares Up 26.0% Since SmarTrend's Buy Recommendation (CPIX)
Comtex SmarTrend(R) - Wed Jan 07, 9:11AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 5 months, Cumberland Pharmaceuticals has returned 26.01% as of today's recent price of $6.08.
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals Remains Attractive After Rally
Daniel Ward - at Seeking Alpha - Tue Jan 06, 5:00AM CST
CPIX: 5.90 (+0.04)
Pleural Effusion Therapeutics Clinical Trials Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 5:31AM CST
The report "Pleural Effusion Global Clinical Trials Review, H2, 2014" provides data on the Pleural Effusion clinical trial scenario. Pleural effusion (water on the lungs) is the build-up of excess fluid between the layers of the pleura outside the lungs. The pleura are a thin covering that lines the surface of the lungs and the inside of the chest wall outside the lungs. The type of fluid that forms a pleural effusion may be categorized as either transudate or exudate. There are many causes of pleural effusions. Some major causes are Congestive heart failure, Kidney failure, Infection, Malignancy, Pulmonary embolism, Hypoalbuminemia, Cirrhosis & Trauma. Approximately 1.5 million pleural effusions are diagnosed in the United States each year. Complete Report is Available @ http://www.reportsnreports.com/reports/322321...-2014.html .
MRK: 58.81 (-0.07), LLY: 70.56 (+0.03), CPIX: 5.90 (+0.04)
Shares of CPIX Up 19.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 23, 11:55AM CST
SmarTrend identified an Uptrend for Cumberland Pharmaceuticals (NASDAQ:CPIX) on August 6th, 2014 at $4.83. In approximately 5 months, Cumberland Pharmaceuticals has returned 19.17% as of today's recent price of $5.75.
CPIX: 5.90 (+0.04)
Why Cumberland Pharmaceuticals Is A Buy After Q3 Earnings
Daniel Ward - at Seeking Alpha - Thu Nov 06, 8:29AM CST
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals EPS of $0.04
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 11:47PM CST
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals' (CPIX) CEO J. Kazimi on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:01PM CST
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 04, 3:05PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2014 financial results.
CPIX: 5.90 (+0.04)
Cumberland Pharmaceuticals To Announce Third Quarter 2014 Financial Results On November 4, 2014
PR Newswire - Tue Oct 21, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2014 financial results after the market closes on Tuesday, November 4, 2014. A conference call and live Internet webcast will be held on Tuesday, November 4, 2014, at 4:30 p.m. Eastern Time to discuss the results.
CPIX: 5.90 (+0.04)
Caldolor® Safely Treats Fever In Hospitalized Children
PR Newswire - Tue Oct 14, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that treatment with intravenous ibuprofen was superior in reducing temperatures in hospitalized, febrile pediatric patients when compared to treatment with oral or suppository acetaminophen. These results were presented at the American Academy of Pediatrics National Conference & Exhibition in San Diego, California.
CPIX: 5.90 (+0.04)
Caldolor® Provides Favorable Inflammatory Response Results In Laparoscopic Cholecystectomy Surgery Patients
PR Newswire - Fri Oct 10, 2:11PM CDT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that preoperative intravenous ibuprofen improved overall quality of recovery in patients undergoing laparoscopic cholecystectomy surgery. These results will be presented at the American Anesthesiology 2014 Annual Meeting in New Orleans, Louisiana.
CPIX: 5.90 (+0.04)
